Latest Regulus Therapeutics Stories
LA JOLLA, Calif., Jan. 3, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 31(st) Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2013 at 11:30 AM PST at the Westin St. Francis Hotel in San Francisco, CA. Additionally,...
CARLSBAD, Calif., Jan. 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 31(st) Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 1:30 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available...
LA JOLLA, Calif., Dec. 20, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it was included on the preliminary list of IPO additions to the Russell 2000® Index to be effective at the close of the U.S. markets on December 21, 2012. The Russell 2000® Index, a subset of the Russell 3000® Index, measures the performance of the small-cap...
LA JOLLA, Calif., Dec. 3, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it will host The NASDAQ Stock Market Closing Bell at the NASDAQ MarketSite in Times Square, New York on December 5, 2012. Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will ring The NASDAQ Stock Market Closing Bell. Dr. Xanthopoulos will be...
LA JOLLA, Calif., Nov. 27, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Victor Knopov, Ph.D. to its executive management team as Vice President, Pharmaceutical Development. Dr. Knopov joined Regulus from Nitto Denko Technical Corporation where he served as Director, Chemistry Manufacturing Control since 2010. "Victor...
CARLSBAD, Calif., Nov. 20, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 24(th )Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2012 at 1:00 p.m. ET in New York, NY. A live audio webcast of the presentation and panel will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be...
LA JOLLA, Calif., Nov. 19, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended September 30, 2012 and provided a summary of recent corporate highlights. "The third quarter and subsequent period were the most successful to date for Regulus as measured by the achievement of significant financial and strategic...
LA JOLLA, Calif., Nov. 12, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended September 30, 2012 on Monday, November 19, 2012, after the U.S. financial markets close. Regulus will host a conference call and webcast on Monday, November 19, 2012 at 5:00 pm Eastern Standard...
CARLSBAD, Calif., Nov. 8, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2012 Credit Suisse Healthcare Conference on Thursday, November 15, 2012 at 9:00 a.m. MT in Phoenix, AZ. A live audio webcast of the presentation and panel will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available...
LA JOLLA, Calif., Nov. 7, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Douglas E. Williams, Ph.D. to its Board of Directors. Concurrently, Stanley T. Crooke, M.D., Ph.D., Chairman of the Board and CEO of Isis Pharmaceuticals, Inc., and Barry E. Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals,...
